ImmunityBio lifts Anktiva data profile, shares stay in focus on Nasdaq
22.06.2026 - 20:10:35 | ad-hoc-news.de
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-22, 20:08.
ImmunityBio Inc. (US45258J1025) remains in the biotech spotlight on Nasdaq as investors digest fresh clinical data presentations on Anktiva alongside a detailed post-earnings assessment from Zacks Investment Research. The stock has already logged a triple-digit year-to-date gain, putting execution under closer scrutiny according to recent commentary.
What recent reports highlight
At the start of June, ImmunityBio showcased new clinical and comparative data for its IL-15 superagonist Anktiva across lung and bladder cancer at the ASCO 2026 meeting, underlining management’s focus on expanding indications beyond non-muscle invasive bladder cancer.Stocktwits news overview on ImmunityBio The presentations build on the U.S. launch of Anktiva and a growing stream of international roll-outs that have attracted retail traders’ attention.
A recent Zacks analysis notes that ImmunityBio shares changed hands at around 7.72 dollars on May 28, 2026 after a roughly 289.9 percent year-to-date surge, framing the current setup as more about what is already priced in than about the next headline alone.Zacks review of ImmunityBio after Q1 and FDA update Zacks describes the near-term base case as an in-line performance path closely tied to Anktiva’s commercial trajectory.
Numbers after the first quarter
For the first quarter of 2026, Zacks reports that ImmunityBio posted an adjusted loss of 0.09 dollars per share, slightly wider than the consensus loss estimate of 0.08 dollars per share, reflecting continued investment in commercialization and R&D.Zacks analysis of ImmunityBio’s Q1 results Revenue reached 44.2 million dollars versus the 41.1 million dollars expected by analysts, driven primarily by Anktiva sales, pointing to a solid top-line beat despite the modest earnings miss.
Including a sizeable non-cash fair-value adjustment related to warrant and derivative liabilities and a related-party convertible note, the reported loss expanded to 0.62 dollars per share compared with 0.15 dollars a year earlier, underlining how financing structures still shape the GAAP bottom line.Details on non-cash items in ImmunityBio’s Q1 Zacks characterizes the quarter as operationally intact but not clean from an accounting perspective, keeping investors focused on the sustainability of Anktiva’s ramp.
All news and analysis on the ImmunityBio shares
Further ad-hoc disclosures, clinical updates and price data for ImmunityBio are available in the dedicated topic overview and on the company’s Investor Relations page.
How the company earns its money
ImmunityBio’s business model centers on immunotherapy platforms that stimulate both innate and adaptive immunity, with Anktiva as the first commercial pillar in oncology. The company is developing a pipeline of IL-15-based cytokine fusion proteins, cell therapies and vaccine candidates aimed at solid tumors and infectious diseases, seeking to diversify revenue beyond the initial bladder cancer indication.Overview of ImmunityBio’s pipeline and focus areas
Where the shares trade today
The ImmunityBio shares (US45258J1025) trade on Nasdaq under the ticker IBRX, last quoted around 7.30 dollars in recent trading, with the stock up strongly year-to-date in the U.S. healthcare sector according to live quote services.
ImmunityBio at a glance
- Company: ImmunityBio, Inc.
- ISIN: US45258J1025
- WKN: A2QKQX
- Ticker: IBRX
- Trading venue: Nasdaq
- Price (as of 2026-06-22, 20:00): 7.30 USD
- Market cap: approximately 3.6 billion USD (as of 2026-06-22)
- Sector / industry: Health Care / Biotechnology
- Index membership: none of the major headline indices such as S&P 500 or Nasdaq-100
- Next earnings date: 2026-08-04
Disclaimer: This article is for informational purposes only and does not constitute investment advice, investment recommendation or an offer or solicitation to buy or sell any financial instrument. All data are based on publicly available sources and may be subject to change. Investors should conduct their own research and, where appropriate, seek professional advice before making investment decisions.
